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Background. Fibromyalgia (FMS) is a pain condition affecting 2–6% ofUS adults; effective treatment remains limited. Determinants
of nonvitamin, nonmineral dietary supplement (NVNM) use among adults with FMS are not well-studied. We investigated the
relation of NVNM use to FMS, and trends, in two nationally representative samples of US adults ≥18 years. Methods. Data were
drawn from 2007 and 2012 National Health Interview Surveys (𝑁’s = 20127 and 30672, resp.). Logistic regression was used
to examine associations of FMS to NVNM use (past 12 months) and evaluate potential modifying influences of gender and
comorbidities. Multivariate models adjusted for sampling design, demographic, lifestyle, and health-related factors. Results. FMS
was significantly higher in 2012 than in 2007 (1.7% versus 1.3%), whereas NVNM use decreased (57% versus 41%; 𝑝 < 0.0001).
Adults reporting diagnosis were more likely to use NVNMs within 12 months, 30 days, or ever relative to adults without;
positive associations remained significant after controlling for demographics, lifestyle characteristics, medical history, and other
confounders (ranges: 2007 and 2012 AORs = 2.3–2.7; 1.5–1.6, resp.; 𝑝’s < 0.0001). Conclusion. In this cross-sectional study of two
national samples, NVNM use was strongly and positively associated with FMS, highlighting the need for further study.
1. Introduction
Fibromyalgia syndrome (FMS) is a rheumatologic neuro-
pathic chronic pain syndrome affecting approximately 2.7%
of populations of all ages across the world [1], including an
estimated 1.8–6.4% of those in the US [2, 3]. FMS is charac-
terized by a constellation of somatic symptoms (e.g., fatigue,
sleep, mood disturbances, and cognitive impairment) that
are typically present in addition to widespread pain [4]; the
etiology of FMS is largely unknown [4]. Additionally, those
with FMSmay also experience high rates of comorbidity, such
as osteoarthritis [5], autoimmune [6], kidney [7], respiratory
[7], and cardiovascular [7, 8] disease, gastrointestinal condi-
tions [7, 9], andheadache [1, 7, 10]. AlthoughFMSaffects both
sexes and people of all ages, the majority of US cases occur in
Caucasian, middle-aged women [11, 12].
The chronic widespread pain characterizing FMS is diffi-
cult to manage, and many physicians remain unfamiliar with
FMS diagnostic criteria and treatment [13] often making it
difficult for patients to obtain an accurate FMS diagnosis
and appropriate care. Although a lack of efficacy evidence
for opioids as FMS treatment exists [14, 15] and opioid over-
dose deaths have more than tripled since 1999 [16, 17],
FMS patients may receive opioid therapy [18]. Common
treatments for FMS include antidepressants, anticonvulsants,
muscle relaxants, and other pain medications [19]. Non-
steroidal anti-inflammatory drugs, which may carry side
effects for as many as 25% of long-term users [20], are not
currently recommended for FMS by any guidelines [19].
Although three drugs are FDA-approved for FMS treatment
[21], these medications may carry significant side effects for
some [22] and are not always effective for all [19]. Thus,
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patients may turn to complementary health approaches
(CHAs, defined as medical/healthcare systems or practices
used outside of mainstreammedicine [23]) to manage symp-
toms [24]; back, neck, and joint pain are among the most
commonly reported conditions for which patients use CHAs
in the US [25, 26].
Nonvitamin, nonmineral dietary supplements (NVNMs)
are a type of CHA used by nearly twenty-five percent of
US adults with a musculoskeletal disorder [25] and include
animal- and plant-derived products (i.e., fish oil, herbal die-
tary supplements).The extent and efficacy ofNVNMs, partic-
ularly herbal dietary supplements, are largely unknown [27,
28]. Although a handful of large surveys have documented
high rates of herbal and other NVNM use for chronic
pain syndromes [24, 25, 29, 30], and anecdotal accounts
indicate that a wide range of herbs have been used for the
treatment of FMS [31], rigorous investigations regarding the
prevalence and correlates of NVNM use in FMS remain
limited. To address these gaps, we assessed the relation of
FMS to NVNM use in two large, representative samples of
US adults and examined potential changes in prevalence rates
for NVNM use among those with FMS over a 5-year time
period.
2. Materials and Methods
2.1. Data Sources. Participants for this studywere drawn from
two nationally representative samples of 23,501 and 34,525US
adults (National Health Interview Surveys (NHIS), 2007 and
2012, resp.). The NHIS is an annual national, cross-sectional
household survey of the noninstitutionalized US population
and is administered by the Centers for Disease Control and
Prevention’s National Center for Health Statistics. A sup-
plement (adult alternative medicine) to the core individual,
family, and household surveys asked participants about use of
a broad range of CHAs, including herbs and other NVNMs,
for both years. All questions were administered in a personal
interview format. Adult response rates to the NHIS were
78.3% in 2007 and 79.7% in 2012, respectively [32].
The NHIS is the only national, public-use survey that
includes comprehensive sets of questions regarding NVNM
and other CHA use. Both 2007 and 2012 surveys used a
stratified multistage probability design weighted on age, sex,
and race/ethnicity, using 2000 and 2010 Census data for each,
respectively. Both surveys oversampled Asian, Black, His-
panic, and minority elderly populations. Thus, each person
in the covered population had a known nonzero probability
of selection. Additional project details have been described
elsewhere [32].
2.2. Study Population. Our analysis excluded participants
who were <18 years of age, were pregnant, had functional
limitation(s) due to senility, had a stroke and used a proxy
to complete the interview, or had current cancer; those
missing data on key covariates were also excluded, as were
participants with extreme values for exercise (>6,000minutes
per week) in order to eliminate potential information bias.
Further exclusion of persons with missing data on FMS and
NVNM use (at 30 days, at 12 months, or ever using NVNMs)
yielded final study samples of 20,127 and 30,672 adults for
2007 and 2012, respectively (Figure 1).
2.3. Variables
2.3.1. Outcome Variables. The main outcome variable for
this study was the reported use of NVNMs within the past
12 months (Y/N). We additionally assessed use of NVNMs
within the previous 30 days (Y/N) and ever (Y/N). Briefly,
survey participants were shown a card with a list of NVNMs
(for which the majority were comprised of herbs or their
compounds; 2007 list: 44 NVNM items with additional
queries for up to two combination supplements, and 2012
list: 21 NVNM items with additional queries for up to two
combination supplements) and queried for a dichotomous
response regarding consumption of any “herbal or other
nonvitamin supplements.” NVNMs included those labelled
“dietary supplement” and in the form of pills, capsules,
tablets, or (2012) liquids (including tinctures) and did not
include homeopathic or cannabis products.
2.3.2. Exposure Variable. Our main exposure was fibromyal-
gia syndrome (FMS) (Y/N), ascertained as an affirmative
response to fibromyalgia after being asked “Have you EVER
been told by a doctor or other health professional that you
had some form of arthritis, rheumatoid arthritis, gout, lupus,
or fibromyalgia? Which of these were you told you had?”
2.3.3. Covariates. Demographics, lifestyle factors, health
conditions, and medical care-related factors known or sus-
pected to be associated with CHAs, NVNM use, and/or
FMS were considered a priori as potential covariates in
multivariate models. Demographic factors assessed included
age, gender, race/ethnicity, education, employment, income,
marital status, geographic region, and place of birth. Addi-
tional related factors included insurance status, annual family
out-of-pocket medical costs, and delay of care due to con-
cerns over cost. Lifestyle factors included smoking status,
alcohol use, exercise, BMI (using the National Institutes of
Health clinical classifications scores) [33], health status, and
substance abuse. Health conditions included self-reported
history of physician-diagnosed diabetes, kidney disease, gas-
trointestinal disorder, respiratory conditions, dyslipidemia,
liver condition, rheumatoid arthritis, cardiovascular disease,
hypertension, nonspecific arthritis, gout, migraines, mental
health condition, insomnia, and previous cancer diagnosis.
These variables are described in greater detail below.
2.4. Statistical Analysis. We conducted complete-case anal-
yses using SAS 9.4 (Cary, NC, USA) and used sampling
weights to account for complex survey procedures; these
were adjusted for the probabilities of selection, nonresponse,
and poststratification [34]. We merged NHIS family, person,
household, sample adult, and adult alternative health files
for each year and measured sample characteristics, including
frequencies/prevalence rates of NVNM use (previous or
current use, past 12 months, and past 30 days) for 2007
and 2012, respectively; we extrapolated estimates to gener-
ate population frequencies using NHIS sampling weights.
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23,393 adult volunteers >18 years (adult RR = 78.3%)
across US (2007 National Health Interview Survey)
Final analyses study sample:
20,127 adults
(1) 5057 adults ever using 
NVNMs, 15070 controls not
using NVNMs
(2) 3582 adults using NVNMs 
in past 12 months, 16545
controls not using NVNMs
(3) 2623 adults using NVNMs 
in past 30 days, 17504
controls not using NVNMs
34,525 adult volunteers >18 years (adult RR = 79.7%)
across US (2012 National Health Interview Survey)
Final analyses study sample:
30,672 adults
(1) 7238 adults ever using 
NVNMs, 23434 controls not
using NVNMs
(2) 5490 adults using NVNMs 
in past 12 months, 25182
controls not using NVNMs
(3) 4120 adults using NVNMs 
in past 30 days, 26552
controls not using NVNMs
these were considered separate categories for analysis
Primary exclusions:
Participants reporting:
(iii) Hx of stroke and required the use of a proxy 
(i) Pregnancy (n = 284)
(ii) Cancer diagnosis (n = 146)
due to physical or mental condition (n = 51)
(iv) Difficulty due to senility (n = 76)
Further exclusion of participants with missing data on 
NVNM use or fibromyalgia (n = 721) or
any other variable of ＣＨＮ？Ｌ？ＭＮ； (n = 2820)
Primary exclusions:
Participants reporting:
(iii) Hx of stroke and required the use of a proxy 
(i) Pregnancy (n = 335)
(ii) Cancer diagnosis (n = 184)
due to physical or mental condition (n = 80)
(iv) Difficulty due to senility (n = 112)
Further exclusion of participants with missing data on 
NVNM use or fibromyalgia (n = 1126) or
any other variable of ＣＨＮ？Ｌ？ＭＮ； (n = 3291)
；
７ith exception of income, which contained >10% of missing values in both datasets;
Figure 1: Study flow diagram for nonvitamin, nonmineral dietary supplement (NVNM) use in two national datasets.
Weighted 𝑡-tests and Rao-Scott Chi-square tests were used
to determine significant differences by NVNM use status for
three outcome time points in both survey years; significant
factors were included in models as covariates. We also used
a DOMAIN statement to keep our exclusions separate while
maintaining the integrity of sampling weights and used Chi-
square and 𝑡-tests to determine significant changes between
2007 and 2012 on weighted frequencies and means of all
items, in addition to number of different NVNMs used,
physician disclosure of NVNM use, and use of other CHAs.
We considered trends between time points significant if there
was no overlap in weighted percentage confidence intervals.
Differences between participants with versus withoutmissing
data were assessed. All 𝑝 values shown are two-sided at 𝑝 ≤
0.05.
Weighted logistic regressions were used to evaluate the
independent associations of FMS diagnosis to NVNM use
in the last 30 days or 12 months or ever. All multivariate
models were adjusted for demographics and medical care-
related factors; additional models also included lifestyle
characteristics and health conditions.
Demographic characteristics included age (evaluated as
both a continuous and categorical variable (18–24, 25–44,
45–64, 65–74, and 75+ years)), sex (male/female), race
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(“non-Hispanic White,” “non-Hispanic Black,” “Hispanic,”
“Asian,” and “other”), marital status (“married/cohabitat-
ing,” “divorced/separated/widowed,” and “single”), educa-
tion (“≤some HS,” “HS/GED,” “some college/AA/tech,” and
“bachelor’s degree+”), employment (“employed for pay,”
“employed but not for pay,” and “unemployed”), income
($1–$24,999; $25,000–$44,999; $45,000–$74,999; $75,000+;
“do not know;” and “missing”), geographic region (“north-
east,” “midwest,” “south,” and “west”), and place of birth (US-
born/other). Medical care-related factors included insurance
status (“uninsured,” “Medicaid,” “Medicare,” “disability,”
and “private”), annual out-of-pocket medical costs (“none”;
<$500; $500–$1999; $2000–$2999; $3000–$4999; $5000 and
over; and “do not know”), and delayed access to care because
they “could not afford” or “worried about cost” (yes/no).
Additional analyses also controlled for lifestyle-related fac-
tors, including BMI (evaluated as continuous and categorical
(<18.5 = “underweight,” 18.5–25 = “underweight or normal
weight,” 25–29.9 = “overweight,” 30–34.9 = “obese class 1,”
and 35+ = “obese classes 2/3”)) [35]; tobacco use (“current
smoker,” “former smoker,” and “never smoked”); alcohol use
(“none,” “light,” and “moderate to heavy”); substance abuse
other than tobacco or alcohol in past year (yes/no); and
physical activity (continuous, in minutes/week).
In our fully adjusted models, we also evaluated the
potentially confounding influence of self-reported health sta-
tus (“excellent/very good/good,” “fair,” and “poor”), specific
health conditions, and total number of health conditions;
this comorbidity index was created from 0–13 participant-
reported conditions, including a history of (1) diabetes;
(2) kidney disease; (3) gastrointestinal disorder (including
history of ulcers, inflammatory/irritable bowel disease, or
constipation severe enough to require medication in the
past year and/or (2012) abdominal pain, digestive allergy,
and/or heartburn in the past year); (4) respiratory conditions
(history of asthma or emphysema and/or chronic bronchitis);
(5) dyslipidemia; (6) liver condition; (7) rheumatoid arthritis;
(8) cardiovascular disease (coronary heart disease, angina,
and/or heart attack); (9) hypertension; (10) nonspecific
arthritis; (11) gout; (12) migraines; and (13) mental health
condition (depression, phobias, and/or being often anxious
in past year and/or ever having bipolar disorder). Health
conditions were evaluated both collectively and individually;
insomnia in the past year and previous cancer diagnosis were
evaluated individually.
We also assessed the potential modifying influence of
gender and presence of comorbid health conditions (0-1
versus 2+) on the association between FMS and NVNM use
at each outcome time point and for each survey year by
including the corresponding multiplicative-interaction term
in age-adjusted models.
3. Results and Discussion
Relative to participants with complete data in both survey
years, those with missing data on key covariates were less
likely to be employed and report high educational attainment
and more likely to be underweight, be older, and indicate
poor reported health status (𝑝’s ≤ 0.0001). Participant age
ranged from 18 to 85 years, averaging 47.5 ± 0.25 and 48.5 ±
0.18 years for 2007 and 2012, respectively. In both years, study
participants were predominantly white (72.2% and 69.5%,
resp.), female (53.1% and 53.5%), and insured (84.3% and
84.2%); most (56.4% and 57.9%) reported they never smoked
cigarettes. Excluding prayer, most participants had used at
least one CHA before (69.8% and 68.8%), and a majority
had also used natural products other than NVNMs (60.4%
and 62.4%) (not shown). In both years, 35% were overweight
(mean BMI = 27.4 ± 0.05 and 27.7 ± 0.04, for 2007 and
2012, resp.), and most (63% and 72%) reported at least one
chronic health condition, with the number of chronic health
conditions increasing from a mean of 1.5 ± 0.02 in 2007 to
1.9 ± 0.01 in 2012.
Table 1 illustrates the distribution of demographic and
lifestyle characteristics, stratified by year and NVNM use
in the past 12 months; medical-related/health characteristics
are displayed in Table 2. The percentage of adults reporting
NVNM use (ever) declined significantly between time points
(𝑝 < 0.0001) from 27.1% of the sample population in 2007
(𝑛 = 5057) to 24.2% in 2012 (𝑛 = 7238; not shown). In
contrast, the percentage of adults reporting use of NVNMs
within the last 12 months (19.1% to 18.5%, resp.) and 30 days
(13.9% in both years; not shown) remained approximately
the same. Prevalence of diagnosed FMS also increased from
1.3% to 1.7% (𝑝 < 0.0001) (Table 3). Consistent with a slight
decrease in overall NVNM use among the general popula-
tion, overall NVNM use among adults diagnosed with FMS
declined from 57% in 2007 to 41% in 2012 (𝑝 < 0.0001).
There were no apparent changes in the number of different
combination NVNM supplements taken among those with
FMS (mean (SE) for past 30 days = 0.99 (0.20) in 2007, 1.1
(0.38) in 2012, 𝑝 = 0.89).
Between 2007 and 2012, rates of NVNM consumption
(past 12 months; Table 1) declined among non-Hispanic
White adults (83% to 79%) but increased among those iden-
tified as Hispanic (7% to 9%; 𝑝’s < 0.0001). Overall, the
likelihood of NVNM use significantly increased by number
of health conditions in both years (Table 2; 𝑝’s for trend
≤ 0.0001, not shown). In addition, NVNM users (past 12
months) spending under $500 in out-of-pocketmedical costs
decreased (2007 and 2012: 35.0% and 31.3%, resp.) while
NVNM users spending over $3,000 increased (6.2% and
8.3%). This was also noted by an increase in likelihood of
NVNM use by out-of-pocket costs for both years (𝑝’s for
trend = 0.0001; not shown). Lastly, consumption of other
natural products (i.e., vitamins/minerals) increased (93% to
96%) among all herbal users between time points.
3.1. Relation of FMS to Herbal Use. Nearly 60% of those with
FMS reported previous or current NVNMuse; 42% indicated
using NVNMs in the past 12 months, and 33% in the past
30 days (Table 3). Approximately 3% of all NVNM users
had FMS; this rate did not differ between years (Table 4).
In 2007, participants with FMS were 3.7 times as likely as
those without FMS to use NVNMs for any length of time
(OR = 3.7, 95% confidence interval (CI): 2.7, 5.0). After
adjustment for demographic, lifestyle, and medical/health
factors, those with FMS were 2.7 times as likely to report
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Table 3: NVNMuse in two nationally representative samples of adults with diagnosed fibromyalgia, National Health Interview Survey (NHIS
2007𝑁 = 221 (1.3%∗C1) versus NHIS 2012𝑁 = 524 (1.7%∗∗C2)).
Characteristic
2007 2012
Overall 𝑝W
𝑁 (%) 95% CI Weighted population
estimate∗
𝑁 (%) 95% CI Weighted population
estimate∗∗
NVNM use ever <0.0001∗∗∗
Yes 114 (57.1) (49.3, 64.9) 624881 204 (40.6) (35.3, 45.8) 633029
No 107 (42.9) (35.1, 50.7) 469162 320 (59.4) (54.2, 64.7) 927192
NVNM use in past 12
months
<0.0001
Yes 82 (41.7) (33.3, 50.2) 456477 157 (31.2) (26.1, 36.4) 487362
No 139 (58.3) (49.8, 66.7) 637566 367 (68.8) (63.6, 73.9) 1072859
NVNM use in past 30
days
<0.0001
Yes 62 (32.7) (24.6, 40.9) 358265 126 (24.5) (19.9, 29.1) 382285
No 159 (67.3) (59.1, 75.4) 735778 398 (75.5) (70.9, 80.1) 1177936
Number of different
NVNM supps in past
30 daystt
(Mean (SE)) 0.99 (0.20) (0.60, 1.4) 1.07 (0.38) (0.32, 1.8) 0.894
Physician disclosure
of NVNMd
<0.0001
Yes 50 (64.6) (53.1, 76.1) 294988 51 (71.4) (59.0, 83.9) 140681
No 32 (35.4) (23.9, 46.9) 161489 15 (28.6) (16.1, 41.0) 56221
Note. Total sample with fibromyalgia is percentage denominator; ∗adjusted for age, sex, and race/ethnicity based on 2000 Census data; ∗∗adjusted for age, sex,
and race/ethnicity based on 2010 Census data; ∗∗∗significant changes between 2007 and 2012 indicated by nonoverlapping weighted population confidence
intervals; W𝑝 values obtained by comparing weighted estimates; note: significant changes between datasets with differing weighting schemes indicated by
nonoverlapping weighted population confidence intervals as ∗ ∗ ∗; ttamong NVNM users with fibromyalgia; including combination NVNM supplement;
dwithin past 30 days (𝑁 = 66; 2007); only disclosure of top therapy assessed within past 12 months (2012); C1(95% CI: 1.1, 1.5); C2(95% CI: 1.6, 1.9).
ever using NVNMs than those without FMS (adjusted odds
ratio (AOR) = 2.7, (CI: 1.9, 3.8)). FMS showed a similarly
strong positive association to recent NVNM use (12-month
and 30-day AORs = 2.3 (CI: 1.5, 3.4) and 2.3 (CI: 1.6,
3.5), resp.). Likewise, FMS was significantly and positively
associatedwith allNVNMuse outcomes in 2012, although the
magnitude of the associations was lower (2012 AORs: herbal
use (ever) = 1.6 (CI: 1.3, 2.0); 12 months = 1.6 (CI: 1.2, 2.0); 30
days = 1.5 (CI: 1.2, 2.0)).
The magnitude of the association of NVNM use to FMS
was significantly greater in those with 0-1 comorbid health
conditions than in those with 2 or more health conditions
(age-adjusted ORs, resp., = 4.7 (CI: 2.2, 9.8) versus 2.8 (CI:
2.0, 3.9; 𝑝 for interaction = 0.008) in 2007; not shown).
However, we found no evidence of a modifying effect of
multiple comorbidities in 2012 or for gender in either year.
To our knowledge, this is the first large, population-based
study to examine the relation of NVNM use to FMS; it is also
among the first rigorous studies to investigate the relation of
NVNM use to any chronic pain condition in a large sample
[25, 29, 30, 36]. Relative to adults without FMS, those with
FMSwere significantlymore likely to report usingNVNMs at
any time point (within the past 30 days or 12 months or ever)
in both 2007 and 2012 survey years; the positive association
of FMS to NVNM use remained highly significant even after
controlling for a broad array of demographic, lifestyle, and
health-related factors.
In our study, the majority of those with FMS indicated
using NVNMs at some time point; one-third had used
NVNMs in the past 30 days. Previous studies assessing herbal
use in FMS reported widely varying rates among FMS
patients, ranging from 43% (FMS = 434) to 78% (FMS = 90)
[36, 37]. Reported rates among other chronic pain popula-
tions have been considerably lower, ranging from 6.8% in a
sample of primary care patients using opioids [29] to 15%
in a primary care patient population with chronic pain [30].
However, percentages given in prior studies were unweighted
and may in part reflect differences in study populations and
outcome definitions, rendering comparisonwith our findings
challenging.
Prevalence of diagnosed FMS increased between 2007
and 2012 (1.3% to 1.7%). Despite lower rates than those
appearing globally and in some US studies [1–3], this appar-
ent rise in diagnosed FMS may be due in part to increased
recognition of FMS by physicians following publication of the
2010 Preliminary ACR updated criteria for fibromyalgia.
In contrast, we found reported NVNM use among adults
with FMSdeclined significantly from2007 to 2012, paralleling
the modest but significant reduction in overall NVNM use
observed between these periods. However, the mean number
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of different combination NVNM supplements used by those
with FMS did not differ between time points and averaged
lower than that reported in a case-control study of North
American women (𝑁 = 434 with FMS) [36]. In addition,
both the observed decline in NVNM use among those with
FMS and the positive but more modest association between
NVNM use and FMS in 2012 compared to 2007 may also
reflect increased availability of FDA-approved FMS medica-
tions following the 2007 NHIS survey administration. It also
remains possible that both the increase in FMS diagnoses and
decrease in odds of NVNM use for FMS over time are also in
part the result of promotion for FMSdrugs by pharmaceutical
companies [38] and increased off-label prescription of other
drugs for FMS, potentially including opioids [39, 40].
Strengths and Limitations. This investigation was the first
study to assess the relation between NVNM use and FMS in
a large US population. Strengths of our study include large,
nationally representative samples, use of data from two time
periods, and the availability of comprehensive information
on NVNM use, as well as a broad array of demographic,
lifestyle, health-related, and other potentially confounding
factors. However, there were some limitations. Perhaps most
important, the cross-sectional study design precluded deter-
mination of causal relationships. Ascertainment of NVNM
use and medical history, including diagnosis of FMS, was
reliant on self-report, raising the possibility of recall bias;
however, potential underascertainment would likely bias
our results toward the null, indicating more conservative
estimates.
Although the NVNM use outcome mainly comprised
of herbal dietary supplements and was assessed separately
from many other nonherbal supplements in both NHIS data
collection periods, the nonherbal products coenzyme Q-
10, SAM-e, fish oil, and prebiotics/probiotics were included
in our main NVNM outcome. Thus, our consideration of
a broader NVNM outcome may be more appropriate than
a specific herbal supplement use outcome, since reports
of individual ingredients were not consistently available
between years. There was inadequate capture of certain
herbal products within the NVNM outcome. No data were
available on consumption of herbal and green teas used
for health purposes or on products not labelled (per NHIS
requirements for inclusion) “dietary supplement,” including
home grown herbs, traditionally prepared herbal products,
and bulk herbs/powders sometimes recommended (i.e., by
nutritionists, natural foods purveyors) over widely available
supplements due to quality and processing concerns. We
did not have information on FMS severity or duration, and
although the 2012 questionnaire differed from 2007, there
were no differences with respect to assessment of fibromyal-
gia. Based on cognitive testing and input from expert panels,
the definitions of certain modalities were modified in 2012 to
reduce false-positive responses [34] which may have affected
findings. However, these changes were relatively minor and
were unlikely to affect our estimates, as these potential false-
positives did not vary by disease status.
Given the high prevalence rates of those with FMS using
NVNMs, and the strong, positive relationship of FMS to
NVNM use which persisted in 2012 despite the availability
of approved treatments, additional prospective research is
warranted to confirm these findings, to further investigate
the prevalence, patterns, and determinants of specificNVNM
use in FMS, and to explore the safety and potential efficacy of
NVNM products for this still poorly managed condition.
4. Conclusions
In the first large cross-sectional study of two nationally
representative samples of US adults, reported diagnosis of
FMS was strongly and positively associated with NVNM use
in both 2007 and 2012 after adjustment for demographic,
lifestyle, and health factors. Rigorous prospective studies are
needed to confirm these findings and to further explore the
patterns, determinants, and potential efficacy of NVNM use
in those with FMS.
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